Wednesday, April 20, 2022 8:18:19 PM
O/S will be 12,035,633
Based on 7,129,778 shares of common stock outstanding as of March 28, 2022, and assumes that following the offering all of the 4,905,855 Private Placement Warrants will have been exercised (such that 12,035,633 shares of common stock will be outstanding), and all of the shares offered by the selling stockholders hereunder will have been sold.
Based on 7,129,778 shares of common stock outstanding as of March 28, 2022, and assumes that following the offering all of the 4,905,855 Private Placement Warrants will have been exercised (such that 12,035,633 shares of common stock will be outstanding), and all of the shares offered by the selling stockholders hereunder will have been sold.
Recent SBFM News
- Sunshine Biopharma Receives Canadian Regulatory Approval for Generic Amoxicillin • ACCESS Newswire • 05/21/2026 11:00:00 AM
- Sunshine Biopharma Inc. Announces Closing of up to $18.0 Million Public Offering • ACCESS Newswire • 05/19/2026 04:05:00 PM
- Sunshine Biopharma Inc. Announces Pricing of $6.0 Million Public Offering • ACCESS Newswire • 05/18/2026 04:15:00 PM
- Sunshine Biopharma Reports Fiscal 2025 Revenue of $36.3 Million, a 4.1% Increase Over Prior Year • ACCESS Newswire • 04/06/2026 12:30:00 PM
- Sunshine Biopharma Gains FDA-Equivalent Clearance in Canada for Domperidone to Treat Cancer-related Nausea • ACCESS Newswire • 10/28/2025 11:45:00 AM
- Sunshine Biopharma Launches STD, Acne and Lyme Disease Therapy Doxycycline • ACCESS Newswire • 10/20/2025 11:45:00 AM
- Sunshine Biopharma Launches Cholesterol Fighting Medicine Pravastatin • ACCESS Newswire • 10/16/2025 11:45:00 AM
- Sunshine Biopharma Allocates $5 Million for Investment in Bitcoin as Strategic Reserve Asset to Enhance Treasury Resilience • ACCESS Newswire • 10/14/2025 11:00:00 AM
- Sunshine Biopharma and University of Arizona Develop a Potent New Series of Protease Inhibitors for Treatment of SARS Coronavirus Infections • ACCESS Newswire • 10/09/2025 12:00:00 PM
